Our study on Kcnn4/KCa3.1 inhibition recommends advancement of senicapoc pharmacotherapy into clinical trial in patients with ADPKD, initially as sole agent and subsequently, as part of combination therapy. Here, KCNN4 is linked to autosomal dominant polycystic kidney disease.